BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat CIO in H2 2021.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that George Farmer, Ph.D., has been appointed Chief Financial Officer.

IRRAS AB announced that Kleanthis G. Xanthopoulos, Ph.D., the company’s Chief Executive Officer, and Will Martin, the company’s President and Chief Commercial Officer, will provide a company overview and commercial update at the H.C. Wainwright Virtual BioConnect Conference that will be held January 11 - 14, 2021.

Takeda Pharmaceutical Company Limited announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD.

Bay Materials LLC, a leader in high-performance thermoformable plastic materials for orthodontic clear aligner therapy, announced that the U.S. Patent and Trademark office has allowed and issued its second patent for Bay’s “Dual Shell Dental Appliance and Material Constructions” family of patents.

Spinogenix, Inc. announced that it will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s Congressionally Directed Medical Research Programs to evaluate its lead development candidate in ALS.

Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the “Breakthrough Therapy Designation Drug” by the Center for Drug Evaluation and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer with disease progression or recurrence after two lines of prior systematic chemotherapy.

Nxt-ID, Inc., a provider of healthcare devices and services, announced that on January 4, 2021, it received written notice from the Office of General Counsel of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.

QT Imaging™, developers of the FDA-cleared QTscan®, has completed a first-in-class and first-in-human study of transmission ultrasound as a new imaging technology for breast health screening.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny’s Chief Executive Officer, will present at the 39th Annual JP Morgan Healthcare Conference